The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Pacira BioSciences Inc shares valued at $9,880 were sold by GAUGLER DARYL on Dec 13 ’24. At $19.76 per share, GAUGLER DARYL sold 500 shares. The insider’s holdings dropped to 115,200 shares worth approximately $2.21 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, GAUGLER DARYL purchased 500 shares, netting a total of over 9,880 in proceeds.
Before that, GAUGLER DARYL had sold 500 shares from its account. In a trade valued at $6,430, the Chief Operating Officer traded Pacira BioSciences Inc shares for $12.86 each. Upon closing the transaction, the insider’s holdings decreased to 500 shares, worth approximately $2.22 million.
As published in a research note from Truist on August 13, 2024, Pacira BioSciences Inc [PCRX] has been rated down from a Buy to a Sell and the price target has been revised to $8 from $30. Analysts at RBC Capital Mkts downgraded the stock from ‘”an Outperform”‘ to ‘”a Sector perform”‘ outlook in a report released in mid August. As of August 12, 2024, Raymond James has decreased its “an Outperform” rating to a “Mkt perform” for PCRX. Earlier on August 12, 2024, Piper Sandler downgraded its rating. Their new recommendation was “a Neutral” for PCRX stock which previously was a “an Overweight”.
Analyzing PCRX Stock Performance
During the last five days, there has been a drop of approximately -5.61%. Over the course of the year, Pacira BioSciences Inc shares have dropped approximately -43.12%. Shares of the company reached a 52-week high of $35.95 on 01/08/24 and a 52-week low of $11.16 on 08/13/24. A 50-day SMA is recorded $17.49, while a 200-day SMA reached $21.81. Nevertheless, trading volume fell to 0.59 million shares from 0.69 million shares the previous day.
Support And Resistance Levels for Pacira BioSciences Inc (PCRX)
According to the 24-hour chart, there is a support level at 18.74, which, if violated, would cause prices to drop to 18.29. In the upper region, resistance lies at 19.99. The next price resistance is at 20.79. RSI (Relative Strength Index) is 57.06 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.62, which suggests the price will decrease in the coming days. Percent R is at 30.67%, indicating low price movement. Stochastics %K at selling indicates that the stock is to be held.
